ICU Medical Shares Upgraded as Analyst Ratings Shift to Buy

Shares of ICU Medical (NASDAQ: ICUI) have been upgraded from a hold to a buy rating by Wall Street Zen, according to a report released on November 11, 2023. This change reflects growing confidence in the medical instruments supplier’s performance, as several other analysts have also revised their ratings and price targets for the stock.

Analyst Ratings and Price Targets

In the same week, KeyCorp adjusted its target price for ICU Medical from $173.00 to $175.00, maintaining an “overweight” rating. Meanwhile, Piper Sandler raised its price objective from $153.00 to $172.00, also rating the stock as “overweight.” Contrarily, Weiss Ratings reiterated a “sell (d-)” rating on the stock in a report dated October 8, 2023.

Currently, one analyst has assigned a strong buy rating to ICU Medical, two analysts rate it as a buy, one maintains a hold rating, and another has issued a sell rating. Overall, the stock holds an average rating of “moderate buy” with a consensus price target of $175.67, according to data from MarketBeat.

Quarterly Earnings Report

ICU Medical recently announced its quarterly earnings on November 6, 2023. The company reported earnings per share (EPS) of $2.03, surpassing the consensus estimate of $1.43 by $0.60. The total revenue for the quarter reached $533.30 million, exceeding analyst expectations of $511.46 million.

Despite this positive earnings report, ICU Medical’s revenue showed a decline of 8.9% compared to the same quarter last year, where it posted an EPS of $1.59. Looking ahead, the company has set its fiscal year 2025 guidance at $7.350 – $7.650 EPS, while sell-side analysts project an EPS of $4.11 for the current year.

Insider Transactions and Institutional Activity

In related news, insider trading activity has been notable. On November 11, 2023, Elisha W. Finney, a director at ICU Medical, sold 1,285 shares at an average price of $140.42, totaling approximately $180,439.70. This sale reduced Finney’s holdings to 3,995 shares, valued at around $560,977.90, a decrease of 24.34%.

Similarly, Virginia Ruth Sanzone, Vice President, sold 930 shares at an average price of $142.34, resulting in a total transaction value of $132,376.20. After this sale, Sanzone owned 5,456 shares valued at roughly $776,607.04, marking a 14.56% decrease in her position.

Institutional investors have shown strong interest in ICU Medical. Millennium Management LLC increased its stake by 173.4% in the third quarter, now holding 1,089,017 shares valued at approximately $130.64 million. Other notable investors include State Street Corp, which raised its position by 3.2%, and Dimensional Fund Advisors LP, which boosted its holdings by 16.9%.

Overall, institutional investors now own approximately 96.10% of ICU Medical’s stock, indicating robust confidence in the company’s future.

Established in 1990, ICU Medical develops and manufactures devices for infusion therapy, vascular access, and vital care applications. Its innovative products include needle-free devices, catheter patency devices, and closed-system transfer devices designed to enhance safety and efficacy in medical treatments.

As ICU Medical continues to navigate the challenges of the medical device market, analysts and investors alike will be watching closely for updates on its performance and strategic direction.